Anthropic says it will one day transform biology

In its IPO filing submitted on Monday, Anthropic described AI transforming biology more cautiously than CEO Dario Amodei's earlier public statements, acknowledging that the company lacks experience in physical experiments. The filing said the team needs first-hand experience in scientific research and drug discovery, that life sciences activities will involve handling potentially dangerous materials, operating experimental equipment and complying with multiple regulations, and that the company no longer positions itself only as an AI tool provider for the biotechnology industry but views biotechnology discovery as part of its core business. Amodei had predicted in an August X post that AI would give humanity a chance to cure most diseases within 5 to 10 years, and in September the company promoted Claude's discovery of a "Crispr-like" enzyme; the IPO filing softened the wording, saying the enzyme may potentially be developed into a new biotechnology tool, perhaps for gene editing. The filing noted that the resulting drug candidates will face the life sciences industry's long, expensive and uncertain development and regulatory path and may never generate revenue.